Whether you’re celebrating a funding round, research collaboration, FDA-approval, or commemorating a deal in the biotech space, you’ll find inspiration in the custom designs below.

Biopharma Stock Offering Tombstone

Custom financial tombstone recognizing a direct offering of common stock by Salarius Pharmaceuticals. The Houston-based firm develops cancer therapies. (22AJH070)

3 Images
Side view of crystal financial tombstone celebrating a direct offering of stock by Salarius Pharmaceuticals. (22AJH070) Back view of DNA strand-inspired financial tombstone marking an offering by clinical-stage firm Salarius Pharmaceuticals. (22AJH070)

Advanced Testing Laboratory Deal Toy

Lucite deal toy recognizing the acquisition of Cincinnati-based Advanced Testing Laboratory. ATL provides research and development services in such areas as life science, product safety, and analytical chemistry. (22AJH077)

1 Image

Pharmaceutical License Agreement Deal Toy

Lucite deal toy celebrating a license option agreement between Ironwood Pharmaceuticals and COUR, a biotech firm. The agreement centers on COUR’s therapy for PBC, a rare autoimmune disease affecting the liver.

(22ALJ081)
2 Images
Lucite deal toy recognizing a joint venture between Ironwood Pharmaceuticals and biotechnology firm COUR. The collaboration will allow Ironwood to develop and commercialize COUR's liver disease therapy CNP-104.

Radiopharm IPO Deal Toy

Crystal deal toy celebrating the initial public offering on the Australian Securities Exchange (ASX) of Radiopharm Theranostics. The Sydney-based company develops radiopharmaceutical drugs and treatments for cancer.

(21ALJ553)
2 Images
Crystal deal toy marking the ASX debut of Sydney-based biotech Radiopharm Theranostics.

Digital Therapeutics Deal Toy

Lucite deal toy, incorporating a spinning logo, celebrating growth capital provided to New York City-based Click Therapeutics. The debt financing will be used for the commercialization of several therapies, including one aimed at smoking cessation.

(21AKL594)
1 Image

Nasdaq IPO Deal Toy

Lucite deal toy celebrating the initial public offering (IPO) of Bluejay Diagnostics. The diagnostics and medical device firm is based in Acton, Massachusetts.

(21AKL655)
1 Image

Test Tube-Inspired Lucite Tombstone

Lucite tombstone commemorating a capital raise by Aditx Therapeutics (Aditxt). The life sciences and biotech firm is based in Richmond, Virginia.

(21AKL251)
1 Image

Gene-Themed Pharmaceutical Deal Tombstone

Lucite deal tombstone commemorating an agreement for global rights to gout treatment drug ARO-XDH. The agreement was reached between Dublin, Ireland-based Horizon Therapeutics and Arrowhead Pharmaceuticals, headquartered in Pasadena, California.

(21ALJ356)
2 Images
Custom Lucite celebrating a deal for global rights to the preclinical "gene-silencing" drug ARO-XDH.

Custom Lucite Embedment with Drug Vial

Lucite embedment with drug vial commemorating a study of a treatment for solid tumor cancer.

(21ADH006)
1 Image

Biotech Deal Toys

Beginning on this page, you’ll find galleries with over 90 images of financial tombstones and deal toys from the biotech and life sciences space. You’ll find a number of custom designs playing off visual elements commonly associated with this space, including DNA strands, pills, lab beakers, periodic tables, as well as ones incorporating actual drug vials.

As you might also expect, you’ll see a number of deal toys involving internationally recognized firms and players. These include Takeda Pharmaceutical, Horizon Therapeutics, Gilead Sciences, Roche, Neurocrine, and Bayer. You’ll see as well tombstones commemorating transactions common to this sector involving these and other firms: joint ventures, licensing deals, and development and commercialization agreements.

But you’ll also notice a number of deals commemorated here that may involve far less familiar firms. These include the acquisition of a Dutch company focused on live-cell imaging analytics, and one of an Illinois-based gene therapy firm devoted to the treatment of a rare genetic disorder; the initial public offering of an Australian developer of radiopharmaceutical cancer therapies, and the IPO of a Norwegian biotech making use of marine compounds such as herring roe extract; early-stage funding for a Philadelphia gene engineering startup, and the IPO of an Israeli firm focused on medical applications for lipid-based compounds.

You’ll also notice in these galleries designs not related to any financial transaction. These celebrate a range of awards and employee recognition pieces honoring successful clinical trials, Food and Drug Administration (FDA) and New Drug Application (NDA) submissions, research collaborations and partnerships, and product development milestones.